UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Breast-cancer detection using blood-based infrared molecular fingerprints

BMC cancer, 2021-12, Vol.21 (1), p.1287-9, Article 1287

2021

Volltextzugriff (PDF)

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma : Results of two randomized trials designed for combined analysis

Cancer, 2001-11, Vol.92 (9), p.2247-2258

2001

Volltextzugriff (PDF)

Triple Negative Breast Cancer: A Tale of Two Decades

Anti-cancer agents in medicinal chemistry, 2017-01, Vol.17 (4), p.491-499

2017

Volltextzugriff (PDF)

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies

NPJ breast cancer, 2021-09, Vol.7 (1), p.124-124, Article 124

2021

Volltextzugriff (PDF)

Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second‐line docetaxel: A randomized trial

Health science reports, 2024-09, Vol.7 (9), p.e70052-n/a

2024

Volltextzugriff (PDF)

Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus

Oncotarget, 2018-04, Vol.9 (28), p.19463-19468

2018

Volltextzugriff (PDF)

Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay—Results From the SAFIA Phase III Trial

JCO global oncology, 2021-12, Vol.7 (7), p.811-819

2021

Volltextzugriff (PDF)

Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?

Critical reviews in oncology/hematology, 2015-07, Vol.95 (1), p.88-104

2015

Volltextzugriff (PDF)

Long-term safety of aromatase inhibitors in the treatment of breast cancer

Therapeutics and clinical risk management, 2008-02, Vol.4 (1), p.189-204

Nabholtz, Jean-Marc A

2008

Volltextzugriff (PDF)

Predictive and prognostic significance of CD8 + tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy

Oncology letters, 2017-07, Vol.14 (1), p.337-344

2017

Volltextzugriff (PDF)

Ocular toxicity and cancer chemotherapy: A review

Cancer, 1996-10, Vol.78 (7), p.1359-1373

1996

Volltextzugriff (PDF)

Responsiveness of the EuroQol in Breast Cancer Patients Undergoing High Dose Chemotherapy

Quality of life research, 2001-01, Vol.10 (6), p.479-486

2001

Volltextzugriff (PDF)

A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites

Journal of pain and symptom management, 2000-03, Vol.19 (3), p.193-199

2000

Volltextzugriff (PDF)

Concurrent weekly carboplatin and radiotherapy for nasopharyngeal carcinoma: report of a joint phase II study

Radiotherapy and oncology, 2001-02, Vol.58 (2), p.131-136

2001

Volltextzugriff (PDF)

Le cancer du sein sans envahissement ganglionnaire. Au-delà des consensus internationaux : une approche pragmatique

Bulletin du cancer, 2011-07, Vol.98 (7), p.807-825

2011

Volltextzugriff (PDF)

Does Regional Lymph Node Irradiation Improve the Outcome of N0 and pN0 Breast Cancer?

Cancer investigation, 2010-02, Vol.28 (2), p.195-200

2010

Volltextzugriff (PDF)

New adjuvant strategies for breast cancer: Meeting the challenge of integrating chemotherapy and trastuzumab (herceptin)

Seminars in oncology, 2001-02, Vol.28 (1D), p.1-12, Article asonc0280001d

2001

Volltextzugriff (PDF)

Main implications related to the switch to BRCA 1/2 tumor testing in ovarian cancer patients: a proposal of a consensus

Oncotarget, 2018-04, Vol.9 (28), p.19463-19468

2018

Volltextzugriff (PDF)

Taxane therapy for early stage breast cancer

Women's Health, 2006-01, Vol.2 (1), p.99-114

2006

Volltextzugriff (PDF)

Final result for SAFIA trial for neoadjuvant palbociclib in patients with operable luminal breast cancer responding to fulvestrant

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.596-596

2022

Volltextzugriff (PDF)

Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer

Indian journal of surgical oncology, 2010, Vol.1 (1), p.19-26

2010

Volltextzugriff (PDF)

A randomized phase III study of vinflunine versus an alkylating agent of physician’s choice in metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinca-alkaloid

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.1031-1031

2015

Volltextzugriff (PDF)

Prediction of response to neoadjuvant hormonal therapy (NAHT) using upfront oncotype Dx recurrence score (RS): Results from the SAFIA phase III trial

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.594-594

2020

Volltextzugriff (PDF)

Abstract OT2-2-01: tnAcity: A phase II/III trial of nab -paclitaxel ( nab -P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC)

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.OT2-2-01-OT2-2-01

2015

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Aktive Filter

ThemaBreast Neoplasms - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(51)

Sprache

Englisch
(50)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Oncology
(15)
Breast Cancer
(13)
Chemotherapy
(12)
Humans
(11)
Female
(9)
Biological And Medical Sciences
(8)
Medical Sciences
(8)
Pharmacology. Drug Treatments
(6)
Antineoplastic Agents
(5)
Cancer
(5)
Middle Aged
(5)
Adult
(4)
Anastrozole
(4)
Breast Neoplasms - Therapy
(4)
Tumors
(4)
Aged
(3)
Antineoplastic Agents - Adverse Effects
(3)
Biomarkers
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Breast-cancer detection using blood-based infrared molecular fingerprints

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma : Results of two randomized trials designed for combined analysis

Triple Negative Breast Cancer: A Tale of Two Decades

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies

Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second‐line docetaxel: A randomized trial

Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus

Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay—Results From the SAFIA Phase III Trial

Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?

Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial

Long-term safety of aromatase inhibitors in the treatment of breast cancer

Predictive and prognostic significance of CD8 + tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy

Ocular toxicity and cancer chemotherapy: A review

Responsiveness of the EuroQol in Breast Cancer Patients Undergoing High Dose Chemotherapy

A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites

Concurrent weekly carboplatin and radiotherapy for nasopharyngeal carcinoma: report of a joint phase II study

Le cancer du sein sans envahissement ganglionnaire. Au-delà des consensus internationaux : une approche pragmatique

Does Regional Lymph Node Irradiation Improve the Outcome of N0 and pN0 Breast Cancer?

New adjuvant strategies for breast cancer: Meeting the challenge of integrating chemotherapy and trastuzumab (herceptin)

Main implications related to the switch to BRCA 1/2 tumor testing in ovarian cancer patients: a proposal of a consensus

Taxane therapy for early stage breast cancer

Final result for SAFIA trial for neoadjuvant palbociclib in patients with operable luminal breast cancer responding to fulvestrant

Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer

A randomized phase III study of vinflunine versus an alkylating agent of physician’s choice in metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinca-alkaloid

Prediction of response to neoadjuvant hormonal therapy (NAHT) using upfront oncotype Dx recurrence score (RS): Results from the SAFIA phase III trial

Abstract OT2-2-01: tnAcity: A phase II/III trial of nab -paclitaxel ( nab -P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC)

Aktive Filter

Suchergebnisse filtern